

Attorney Docket No.: 6001.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Pedersen et al.

Confirmation No: To be assigned

Serial No.: To be assigned

Group Art Unit: To be assigned

Filed: February 28, 2002

Examiner: To be assigned

For: Maltogenic Amylase-Modified Starch Derivatives

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. US 5,958,739
2. WO 99/43793
3. WO 99/43794
4. EP 0 120 693
5. WO 95/10627
6. US 5,763,385
7. US 4,626,288
8. WO 91/00353
9. US 2,661,349
10. US 4,035,235
11. US 3,525,672
12. US 34,428,972
13. US 4,977,252
14. Kirk-Othmer, Encyclopedia of Chemical Technology, 3rd Edition, Vol. 8, pp. 900-930

15. Trubiano, Succinate And substituted Succinate Derivatives Of Starch, Ch. 9, pp.131-147
16. Diderichsen et al., FEMS Microbiology Letters, Vol. 56, pp. 53-60, (1998)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,



Elias J. Lambiris, Reg. No. 33,728
Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

Date: February 28, 2002



